Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $14.00 at Robert W. Baird

Contineum Therapeutics (NASDAQ:CTNM) had its price target cut by Robert W. Baird from $16.00 to $14.00 in a report issued on Monday,Benzinga reports. They currently have an outperform rating on the stock.

Several other analysts have also recently commented on the stock. Morgan Stanley boosted their price target on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. Royal Bank Of Canada reduced their target price on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating on the stock in a report on Friday. Wall Street Zen raised Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Leerink Partners initiated coverage on Contineum Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $22.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.40.

Contineum Therapeutics Price Performance

Shares of CTNM opened at $10.36 on Monday. The firm has a market cap of $302.30 million, a P/E ratio of -4.60 and a beta of 1.27. Contineum Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.25. The company has a 50 day simple moving average of $11.34 and a two-hundred day simple moving average of $7.89.

Contineum Therapeutics (NASDAQ:CTNM) last released its earnings results on Thursday, October 30th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.13. On average, sell-side analysts anticipate that Contineum Therapeutics will post -2.01 earnings per share for the current year.

Institutional Trading of Contineum Therapeutics

Institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. bought a new position in Contineum Therapeutics during the third quarter valued at $24,934,000. Franklin Resources Inc. boosted its stake in shares of Contineum Therapeutics by 7.8% during the 2nd quarter. Franklin Resources Inc. now owns 1,698,825 shares of the company’s stock worth $6,744,000 after purchasing an additional 122,644 shares during the period. Vanguard Group Inc. grew its holdings in Contineum Therapeutics by 29.6% during the 3rd quarter. Vanguard Group Inc. now owns 964,232 shares of the company’s stock valued at $11,330,000 after purchasing an additional 220,231 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in Contineum Therapeutics in the 3rd quarter worth about $11,178,000. Finally, Susquehanna International Group LLP raised its position in Contineum Therapeutics by 914.0% in the 3rd quarter. Susquehanna International Group LLP now owns 204,119 shares of the company’s stock worth $2,398,000 after purchasing an additional 183,988 shares during the period.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).